Evaxion Biotech A/S ADR (EVAX)

Jan 14, 2025, 4:05 PM EST - 3 days ago

Evaxion announces completion of ADS ratio change

Jan 10, 2025, 8:00 AM EST - 7 days ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 18 days ago

Evaxion announces plan to implement ADS ratio change

Nov 12, 2024, 8:00 AM EST - 2 months ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Oct 31, 2024, 8:00 AM EDT - 2 months ago

Evaxion announces business update and third quarter 2024 financial results

Oct 28, 2024, 8:00 AM EDT - 2 months ago

Evaxion to announce business update and third quarter 2024 financial results on October 31

Oct 9, 2024, 8:00 AM EDT - 3 months ago

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Oct 3, 2024, 8:00 AM EDT - 3 months ago

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Sep 26, 2024, 10:53 AM EDT - 4 months ago

Evaxion Biotech Partners With Merck To Expand Vaccine Development

MRK

Sep 26, 2024, 7:30 AM EDT - 4 months ago

Evaxion significantly expands vaccine development collaboration with MSD

Sep 19, 2024, 8:00 AM EDT - 4 months ago

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Sep 9, 2024, 7:00 AM EDT - 4 months ago

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Aug 14, 2024, 11:43 AM EDT - 5 months ago

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 7:27 AM EDT - 5 months ago

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Aug 8, 2024, 8:00 AM EDT - 5 months ago

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

Jul 16, 2024, 7:30 AM EDT - 6 months ago

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Jul 3, 2024, 8:05 AM EDT - 7 months ago

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Jun 26, 2024, 7:30 AM EDT - 7 months ago

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Jun 17, 2024, 8:44 AM EDT - 7 months ago

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

Jun 3, 2024, 8:00 AM EDT - 8 months ago

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024

May 28, 2024, 8:21 AM EDT - 8 months ago

Evaxion Announces Business Update and First Quarter 2024 Financial Results

May 23, 2024, 5:00 PM EDT - 8 months ago

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

May 10, 2024, 5:00 PM EDT - 9 months ago

Evaxion Receives Nasdaq Notification

Apr 17, 2024, 8:00 AM EDT - 9 months ago

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Apr 2, 2024, 2:10 PM EDT - 10 months ago

Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript

Apr 2, 2024, 7:00 AM EDT - 10 months ago

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Mar 27, 2024, 7:30 AM EDT - 10 months ago

Evaxion Announces Business Update and Full Year 2023 Financial Results

Mar 19, 2024, 7:30 AM EDT - 10 months ago

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Feb 29, 2024, 7:30 AM EST - 11 months ago

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Feb 20, 2024, 7:30 AM EST - 11 months ago

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Feb 7, 2024, 8:30 AM EST - 1 year ago

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 6, 2024, 8:30 AM EST - 1 year ago

Evaxion Announces Closing of $15 Million Public Offering

Feb 1, 2024, 9:20 AM EST - 1 year ago

Evaxion Biotech Announces Pricing of $15 Million Public Offering

Jan 24, 2024, 9:58 AM EST - 1 year ago

This AI-enabled biotech stock nearly doubled on Wednesday: here's why

Jan 24, 2024, 8:30 AM EST - 1 year ago

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Jan 22, 2024, 4:30 PM EST - 1 year ago

Evaxion Announces Completion of ADS Ratio Change

Jan 8, 2024, 8:30 AM EST - 1 year ago

Evaxion Announces Plan to Implement ADS Ratio Change

Dec 21, 2023, 4:30 PM EST - 1 year ago

Evaxion Biotech Announces Closing of Private Placement

Dec 19, 2023, 4:15 PM EST - 1 year ago

Evaxion Announces Business Update and Third Quarter 2023 Financial Results

Dec 19, 2023, 9:25 AM EST - 1 year ago

Evaxion Biotech Announces Private Placement Financing

Nov 28, 2023, 8:27 AM EST - 1 year ago

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Nov 15, 2023, 8:00 AM EST - 1 year ago

Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy

Nov 6, 2023, 10:12 AM EST - 1 year ago

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak

Oct 31, 2023, 11:15 AM EDT - 1 year ago

Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01

Oct 26, 2023, 8:30 AM EDT - 1 year ago

New and Exciting Clinical Data on Evaxion's AI-Immunology™-Based Personalized Cancer Vaccines to be Presented

Oct 5, 2023, 8:30 AM EDT - 1 year ago

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Sep 20, 2023, 8:26 AM EDT - 1 year ago

Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea

Sep 18, 2023, 8:23 AM EDT - 1 year ago

Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company

Sep 11, 2023, 8:17 AM EDT - 1 year ago

Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

Aug 29, 2023, 8:30 AM EDT - 1 year ago

Evaxion announces Executive Management Changes to strengthen the AI-strategy